MedTrace Logo

MitoQ for Fatigue in Multiple Sclerosis (MS)

NCT04267926 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

Conditions

Interventions

DRUG

20 mg MitoQ

a third of subject will receive 20mg of oral MitoQ

DRUG

Placebo

Subject will receive Placebo

DRUG

40mg of MitoQ

a third of subjects will receive 40mg of MitoQ

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Vijayshree Yadav, MBBS · VA Portland Health Care System, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2024-10-15
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04267926 on ClinicalTrials.gov